Fingolimod tedavisi alan multiple skleroz hastalarında lenfopeninin yaş ve cinsiyet ile ilişkisi
Yükleniyor...
Dosyalar
Tarih
2020
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Hatay Mustafa Kemal Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Hatay Mustafa Kemal Üniversitesi Tıp Fakültesi Nöroloji Anabilim Dalı Multipl Skleroz polikliniğinde Multipl Skleroz tanısı ile takip edilen ve fingolimod tedavisi alan hastalarda görülen lenfopeni ile yaş ve cinsiyet faktörleri arasındaki ilişkinin araştırılması amaçlandı. Gereç ve Yöntem: Çalışma retrospektif bir araştırma olup, hastanemiz poliklinik veri tabanına kayıtlı Multiple Skleroz hastalarından 63 kadın 63 erkek toplam 126 Relapsing Remitting Multiple Skleroz hastasına ait yaş, fingolimod kullanmadan önce ve kullandıktan 1 ay sonra lenfosit sayıları kaydedildi ve istatistiksel olarak değerlendirildi. Bulgular: Çalışmamızda, Relapsing Remitting Multipl Skleroz hastalarında 0,5 mg/gün dozunda oral fingolimod tedavisi başlandıktan en erken 1 ay sonrasında bakılan ortalama lenfosit sayılarının (745,10 ± 681,63/μl), tedaviye başlanmadan önceki ortalama lenfosit sayılarına göre düşük olduğu saptandı (p<0,001). 0.80 x 10^3/μl altındaki hastalar lenfopeni olarak değerlendirildi. Fingolimod tedavisi alan Multipl Skleroz hastalarında görülen lenfopeni ile yaş faktörü arasında anlamlı bir ilişki bulunamadı (p>0,05). Lenfopeni ile cinsiyet arasındaki ilişki değerlendirildi, 63 kadın hastanın 54 ünde,63 erkek hastanın 43 'ünde lenfopeni görüldü ve kadın hastalarda lenfopeni riskinin daha yüksek olduğu bulundu (p<0,001). Fakat lenfopeni görülen kadın ve erkek hastaların tedavi sonrası lenfosit ortalamaları arasında anlamlı bir farklılık saptanmadı. Sonuç: Çalışmamızda fingolimoda bağlı lenfopeni riskinin kadınlarda daha fazla olduğu, yaş faktörünün ise literatür ile uyumlu olarak risk oluşturmadığı görülmüştür.
Aim: The aim of this study was to investigate the relationship between lymphopenia and age and gender factors observed in Multiple Sclerosis patients who were followed-up with Multiple Sclerosis diagnosis and were treated with fingolimod for the first time in the MS outpatient clinic of Neurology of Medical Faculty at Department Hatay Mustafa Kemal University. Material and Method: Our study is a retrospective study and 63 women, 63 men, a total of 126 Relapsing Remitting Multiple Sclerosis patients registered in the polyclinic database of our hospital, age, lymphocyte counts were recorded before and after using fingolimod and statistically evaluated. Results: In our study, it was found that the mean lymphocyte counts (745,10 ± 681,63/μl ) examined at the earliest 1 month after starting oral finglimod (0,5mg/day) treatment in Relapsing Remitting Multiple Sclerosis patients were lower than the mean lymphocyte counts before starting any treatment (p <0.001). Patients below 0.80 x 10 ^ 3 / μl were evaluated as lymphopenia. There was no correlation between lymphopenia and age factor in Multiple Sclerosis patients receiving fingolimod treatment (p> 0.05). The relationship between lymphopenia and gender was evaluated and lymphopenia was observed in 54 of 63 female patients and 43 of 63 male patients. Female patients were found to have a higher risk of lymphopenia (p <0.001). However, no statistically significant difference was found between lymphocyte averages after treatment of male and female patients with lymphopenia. Conclusions: In our study, it was observed that the risk of fingolimod-induced lymphopenia was higher in women, and the age factor did not pose a risk in accordance with the literature.
Aim: The aim of this study was to investigate the relationship between lymphopenia and age and gender factors observed in Multiple Sclerosis patients who were followed-up with Multiple Sclerosis diagnosis and were treated with fingolimod for the first time in the MS outpatient clinic of Neurology of Medical Faculty at Department Hatay Mustafa Kemal University. Material and Method: Our study is a retrospective study and 63 women, 63 men, a total of 126 Relapsing Remitting Multiple Sclerosis patients registered in the polyclinic database of our hospital, age, lymphocyte counts were recorded before and after using fingolimod and statistically evaluated. Results: In our study, it was found that the mean lymphocyte counts (745,10 ± 681,63/μl ) examined at the earliest 1 month after starting oral finglimod (0,5mg/day) treatment in Relapsing Remitting Multiple Sclerosis patients were lower than the mean lymphocyte counts before starting any treatment (p <0.001). Patients below 0.80 x 10 ^ 3 / μl were evaluated as lymphopenia. There was no correlation between lymphopenia and age factor in Multiple Sclerosis patients receiving fingolimod treatment (p> 0.05). The relationship between lymphopenia and gender was evaluated and lymphopenia was observed in 54 of 63 female patients and 43 of 63 male patients. Female patients were found to have a higher risk of lymphopenia (p <0.001). However, no statistically significant difference was found between lymphocyte averages after treatment of male and female patients with lymphopenia. Conclusions: In our study, it was observed that the risk of fingolimod-induced lymphopenia was higher in women, and the age factor did not pose a risk in accordance with the literature.
Açıklama
Anahtar Kelimeler
Nöroloji, Neurology, Fingolimod, relapsing remitting multipl skleroz, lenfopeni, Fingolimod, relapsing remitting multiple sclerosis, lymph
